Table 2.
Clinical outcomes in patients with migraine without aura during the study period.
| Assessment points (wks) | Days with migraine | VAS score | MSQ score, restrictive subscale | MSQ score, preventive subscale | MSQ score, emotional functional subscale | SAS score | SDS score | P-value for pairwise comparison | |
|---|---|---|---|---|---|---|---|---|---|
| VS baseline | VS treatment | ||||||||
| Baseline, −4–0 |
5.16 (1.66) | 7.73 (1.41) | 55.14 (14.81) | 61.49 (20.91) | 62.52 (23.06) | 43.76 (9.33) | 47.38 (9.80) | <0.001 | |
| Treatment, 1–6 |
1.57 (1.21) | 4.08 (1.26) | 75.21 (13.15) | 83.38 (14.96) | 83.42 (15.53) | 39.73 (8.84) | 40.38 (10.61) | <0.001 | |
| Follow-up, 7–10 |
1.16 (0.99) | 4.49 (1.48) | 78.61 (13.38) | 85.68 (13.75) | 84.32 (14.42) | 39.46 (8.24) | 41.03 (11.40) | <0.001 | >0.05 |
| Follow-up, 11–18 |
1.54 (0.77) | 4.43 (1.46) | 78.07 (12.90) | 85.27 (11.30) | 84.50 (13.25) | 39.49 (8.51) | 39.89 (11.03) | <0.001 | >0.05 |
| Follow-up, 19–30 |
1.44 (0.70) | 4.89 (1.08) | 74.29 (14.00) | 80.00 (12.83) | 83.70 (11.70) | 40.97 (7.98) | 42.70 (9.62) | <0.001 | >0.05 |
Data are shown as the mean (standard deviation). The P-values indicate the results of one-way analysis of variance for comparison between different periods of treatment in the migraine group. MSQ, Migraine-Specific Quality of Life Questionnaire; SAS, Self-Rating Anxiety Scale; SDS, Self-Rating Depression Scale; VAS, visual analog scale.